[Adjuvant surgery for advanced gastric cancer]

Gan To Kagaku Ryoho. 2010 Feb;37(2):263-6.
[Article in Japanese]

Abstract

Purpose: The purpose of this study was to evaluate the efficacy of(adjuvant)surgery following the response to chemotherapy for advanced gastric cancer.

Subjects and methods: The subjects were 20 advanced gastric cancer patients who had undergone gastrectomy following the response to combination chemotherapy with docetaxel and S-1 from September 2003 to December 2008. They consisted of 14 men and 6 women, with a median age of 58. 8, who received combination chemotherapy with docetaxel and S-1 according to the following regimen: S-1, 80 mg/m2, was administered on 14 consecutive days followed by a 7-day rest period, and docetaxel, 40 mg/m2, was administered on day 1.

Results: The average treatment was 4. 4 courses. They consisted of 17 PR and 3 SD. The median overall survival was 855 days. 2-year and 3-year survival was seen in 80% and 54. 9% of patients, respectively, following macroscopically curative operation. Median survival of patients with liver metastasis and peritoneal dissemination was 865 days and 510 days, respectively.

Conclusion: Adjuvant surgery might be effective in advanced gastric cancer patients except for cases of peritoneal dissemination.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Chemotherapy, Adjuvant
  • Docetaxel
  • Drug Combinations
  • Female
  • Follow-Up Studies
  • Gastrectomy
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Oxonic Acid / administration & dosage
  • Oxonic Acid / therapeutic use*
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / surgery*
  • Survival Rate
  • Taxoids / administration & dosage
  • Taxoids / therapeutic use*
  • Tegafur / administration & dosage
  • Tegafur / therapeutic use*

Substances

  • Antineoplastic Agents
  • Drug Combinations
  • Taxoids
  • S 1 (combination)
  • Tegafur
  • Docetaxel
  • Oxonic Acid